Items Tagged ‘T790 mutation’

December 19th, 2016

Tagrisso®: New Standard of Care for Certain Lung Cancer


Treatment with the targeted agent Tagrisso (osimertinib) significantly delayed cancer progression, and resulted in fewer side effects, than standard chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) whose cancer had progressed following prior therapy with an epidermal growth factor receptor (EGFR) inhibitor. Lung cancer remains the leading cause of cancer-related deaths in the […]

View full entry

Tags: EGFR, epidermal growth factor receptor, General Lung Cancer, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, osimertinib, Stages IIIB-IV Lung Cancer - Non-Small Cell, T790 mutation, tagrisso